2018 Global Healthcare Conference
#BairdHCC
Global Healthcare Conference imagery - Composite Photo of Healthcare related imagery

The Pulse of Healthcare

Experts from across Baird's integrated Healthcare platform offer timely sector insights in conjunction with Baird's 2018 Global Healthcare Conference.

How Technology is Reshaping the Future of Medicine

READ MORE

Is This a Golden Age for Biotech?

READ MORE

What's Behind the Robust Investment in Pharma Services M&A?

READ MORE

How Technology is Reshaping the Future of Medicine

Technology is not only driving medical breakthroughs – it is revolutionizing healthcare by creating new business models and transformative opportunities for innovation. Baird Capital examines this convergence of biology and technology and the current investment landscape.

Is this a Golden Age for Biotech?

Biotech has contributed to numerous recent medical advances – but can it continue to innovate in the face of pressure to lower drug prices and investor concern? Baird's senior analyst covering the sector discusses challenges, opportunities and the next potential breakthrough in this Q&A.

What's Behind the Robust Investment in Pharma Services M&A?

Strategic buyers and financial sponsors alike are targeting outsourced pharma services assets. What is commanding buyers' interest, and what lies ahead for the sector? Baird Global Investment Banking weighs in on the drivers of this strong activity.

Specialization Spurs Evolving Biopharma Landscape

Biotech's research and development focus is shifting toward specialty therapy areas. How can firms differentiate themselves as the sector evolves? Baird Capital discusses the changing market and its recent experience in the space.

Charting the Last Mile of Care

Healthcare organizations are looking for clinical workflow and automation technology that translates data into action – and buyers are eager to acquire attractive assets. Baird Global Investment Banking investigates current investment drivers and buyer dynamics.

What's in Store for Biotech?

After a tough 2016 and amid the ongoing debate over U.S. healthcare legislation, Biotech is on the rebound. Baird's senior research analyst covering Biotech explores the impact of political uncertainty, changes at the FDA and market dynamics in this Q&A.